SynthesisBMC pulmonary medicine2022
A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.
Synthesis in BMC pulmonary medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Economic Burden of Idiopathic Pulmonary Fibrosis: Updated Evidence on Costs and Resource Use.PharmacoEconomics · 2026Pooled it
- Economic burden and cost drivers of interstitial lung disease: a systematic review.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Pooled it
- Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury: A modeling study.PLoS medicine · 2026Article
- Beyond Technological Access: Exploring Contextual Factors Related to Teleassessment Usability in Interstitial Lung Disease.International journal of environmental research and public health · 2026Article
- Assessing the real-world impact of interstitial lung disease in patients with rheumatoid arthritis on healthcare resources and treatment patterns through natural language processing.EULAR rheumatology open · 2026Article
- Article
- Telemedicine in chronic lung disease management: progress and prospects.The Korean journal of internal medicine · 2026Review
- Global Burden of Disease of interstitial lung disease and pulmonary sarcoidosis in adolescents and young adults (1990-2019), and projections for the next 30 years.European journal of medical research · 2025Article
- Healthcare Expenditures and Reimbursement Patterns in Idiopathic Pulmonary Fibrosis: A 10-Year Single-Center Retrospective Cohort Study in Turkey.Healthcare (Basel, Switzerland) · 2025Article
- Global epidemiology and burden of interstitial lung disease.The Lancet. Respiratory medicine · 2025Review
- Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People.Drugs & aging · 2025Review
- Epidemiological analysis and temporal trends of interstitial lung diseases in global, Chinese, and Belt and Road Initiative countries: 1990-2021.Frontiers in medicine · 2025Article
- Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.Journal of managed care & specialty pharmacy · 2025Review
- Computational deconvolution of cell type-specific gene expression in COPD and IPF lungs reveals disease severity associations.BMC genomics · 2024Article
- Article
- Impact of ambient temperature on respiratory disease: a case-crossover study in Seoul.Respiratory research · 2024Article
- Interstitial Lung Disease and Sarcoidosis.Clinics in chest medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe economic burden of interstitial lung disease (ILD) is unknown, limiting informed resource allocation and planning. We sought to conduct the first systematic review on the direct, indirect, and overall costs associated with ILD and to evaluate the cost-effectiveness of current therapies globally.
methodsWe conducted systematic reviews of ILD disease cost studies and cost-effectiveness analyses (CEAs) using MEDLINE, Embase, and Web of Science databases between 2000 and 2020. We compared ILD costs between countries according to the share of costs towards each country's respective gross domestic product (GDP) per capita. Costs are reported in 2020 USD.
resultsWe identified 25 disease cost studies and 7 CEAs. The direct medical costs ranged between $1824 and $116,927 annually per patient (median $32,834; 14-180% of GDP per capita in Western countries). The leading drivers of direct costs were inpatient (55%), outpatient (22%), and medication costs (18%), based on pooled estimates. Annual indirect costs ranged from $7149 to $10,902 per employed patient (median $9607; 12-23% of GDP per capita). Among the 7 CEAs, only 1 study (14%) showed an ILD therapy (ambulatory oxygen) was cost-effective compared to best supportive care.
conclusionThe direct and indirect costs associated with ILD are consistently high in all countries with available data, with cost-effectiveness profiles of new therapies generally undesirable. Globally, the median total direct cost for ILD equates to 51% of a country's GDP per capita and has been increasing over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.